Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis

Abstract Sildenafil is a phosphodiesterase-5 inhibitor used to treat idiopathic pulmonary arterial hypertension; however, its benefits are unclear in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate its effect as an add-on to antifibrotic agents on clinical outcomes o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jieun Kang, Jin Woo Song
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/98744e44e4c2472da78b957c76dcc9cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:98744e44e4c2472da78b957c76dcc9cc
record_format	dspace
spelling	oai:doaj.org-article:98744e44e4c2472da78b957c76dcc9cc2021-12-02T18:03:05ZEffect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis10.1038/s41598-021-97396-z2045-2322https://doaj.org/article/98744e44e4c2472da78b957c76dcc9cc2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97396-zhttps://doaj.org/toc/2045-2322Abstract Sildenafil is a phosphodiesterase-5 inhibitor used to treat idiopathic pulmonary arterial hypertension; however, its benefits are unclear in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate its effect as an add-on to antifibrotic agents on clinical outcomes of real-world IPF patients. Among a total of 607 IPF patients treated with antifibrotic agent, 66 concurrently received sildenafil. Propensity score matching was performed to adjust for differences in age, sex, body mass index, forced vital capacity (FVC), and diffusing capacity (DLCO) between the sildenafil and no-sildenafil groups. The outcomes of these groups in terms of FVC decline rate, all-cause mortality, hospitalization, and acute exacerbation were compared. Propensity score matching identified 51 matched pairs. The mean age of the patients was 69.5 years and 80.4% were male. Mean FVC and DLCO were 51.7% and 29.5% of the predicted values, respectively. The FVC decline rates did not differ significantly (p = 0.714) between the sildenafil (− 101 mL/year) and no-sildenafil (− 117 mL/year) groups. In multivariable analyses adjusted for comorbidities and presence of pulmonary hypertension, sildenafil had no significant impact on all-cause mortality, hospitalization, or acute exacerbation. Sildenafil add-on to antifibrotic treatment had no significant effects on the clinical outcomes of IPF patients.Jieun KangJin Woo SongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jieun Kang Jin Woo Song Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
description	Abstract Sildenafil is a phosphodiesterase-5 inhibitor used to treat idiopathic pulmonary arterial hypertension; however, its benefits are unclear in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate its effect as an add-on to antifibrotic agents on clinical outcomes of real-world IPF patients. Among a total of 607 IPF patients treated with antifibrotic agent, 66 concurrently received sildenafil. Propensity score matching was performed to adjust for differences in age, sex, body mass index, forced vital capacity (FVC), and diffusing capacity (DLCO) between the sildenafil and no-sildenafil groups. The outcomes of these groups in terms of FVC decline rate, all-cause mortality, hospitalization, and acute exacerbation were compared. Propensity score matching identified 51 matched pairs. The mean age of the patients was 69.5 years and 80.4% were male. Mean FVC and DLCO were 51.7% and 29.5% of the predicted values, respectively. The FVC decline rates did not differ significantly (p = 0.714) between the sildenafil (− 101 mL/year) and no-sildenafil (− 117 mL/year) groups. In multivariable analyses adjusted for comorbidities and presence of pulmonary hypertension, sildenafil had no significant impact on all-cause mortality, hospitalization, or acute exacerbation. Sildenafil add-on to antifibrotic treatment had no significant effects on the clinical outcomes of IPF patients.
format	article
author	Jieun Kang Jin Woo Song
author_facet	Jieun Kang Jin Woo Song
author_sort	Jieun Kang
title	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
title_short	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
title_full	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
title_fullStr	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
title_full_unstemmed	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
title_sort	effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/98744e44e4c2472da78b957c76dcc9cc
work_keys_str_mv	AT jieunkang effectofsildenafiladdedtoantifibrotictreatmentinidiopathicpulmonaryfibrosis AT jinwoosong effectofsildenafiladdedtoantifibrotictreatmentinidiopathicpulmonaryfibrosis
_version_	1718378823663222784

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis

Ejemplares similares